Synlogic (NASDAQ:SYBX) – Wedbush upped their Q1 2018 earnings per share (EPS) estimates for Synlogic in a research report issued on Tuesday, March 13th, according to Zacks Investment Research. Wedbush analyst D. Nierengarten now expects that the biotechnology company will earn ($0.62) per share for the quarter, up from their previous forecast of ($0.84). Wedbush also issued estimates for Synlogic’s Q2 2018 earnings at ($0.65) EPS, Q3 2018 earnings at ($0.69) EPS, Q4 2018 earnings at ($0.73) EPS, FY2018 earnings at ($2.68) EPS, FY2019 earnings at ($2.54) EPS, FY2020 earnings at ($2.37) EPS and FY2021 earnings at ($2.25) EPS.
Other equities research analysts have also issued reports about the company. HC Wainwright set a $20.00 price target on Synlogic and gave the company a “buy” rating in a research report on Wednesday. ValuEngine lowered Synlogic from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Zacks Investment Research lowered Synlogic from a “hold” rating to a “sell” rating in a research report on Wednesday, January 31st. Finally, Piper Jaffray began coverage on Synlogic in a research report on Monday, January 29th. They set an “overweight” rating and a $16.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $19.00.
Shares of SYBX stock traded up $0.52 on Friday, hitting $9.70. 196,520 shares of the stock traded hands, compared to its average volume of 91,541. The company has a current ratio of 9.82, a quick ratio of 9.82 and a debt-to-equity ratio of 0.01. The firm has a market cap of $203.54, a P/E ratio of -1.65 and a beta of 2.22. Synlogic has a 1-year low of $8.76 and a 1-year high of $23.00.
Synlogic (NASDAQ:SYBX) last posted its quarterly earnings results on Tuesday, March 20th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.07. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.11 million.
Hedge funds and other institutional investors have recently modified their holdings of the business. Spark Investment Management LLC acquired a new stake in Synlogic in the fourth quarter worth $105,000. Deutsche Bank AG increased its position in Synlogic by 204.0% in the fourth quarter. Deutsche Bank AG now owns 19,672 shares of the biotechnology company’s stock worth $190,000 after buying an additional 13,200 shares during the period. Renaissance Technologies LLC acquired a new stake in Synlogic in the fourth quarter worth $191,000. Finally, Artal Group S.A. acquired a new stake in Synlogic in the fourth quarter worth $5,335,000. 48.97% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Wedbush Analysts Boost Earnings Estimates for Synlogic (NASDAQ:SYBX)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/04/07/q1-2018-earnings-forecast-for-synlogic-inc-sybx-issued-by-wedbush.html.
Synlogic, Inc develops synthetic biotic medicines for the treatment of patients with urea cycle disorder and phenylketonuria. The company is based in Cambridge, Massachusetts.
Get a free copy of the Zacks research report on Synlogic (SYBX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.